Sophia Genetics SA
SOPH4.780USD
+0.170+3.69%
收盤 12/22, 16:00（美東）報價延遲15分鐘
324.31M總市值
虧損本益比TTM
關於 Sophia Genetics SA 公司
SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.
Sophia Genetics SA簡介
公司代碼SOPH
公司名稱Sophia Genetics SA
上市日期Jul 23, 2021
CEOCamblong (Jurgi)
員工數量423
證券類型Ordinary Share
年結日Jul 23
公司地址La Piece 12
城市ROLLE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Switzerland
郵編CH-1180
電話41216941060
網址https://www.sophiagenetics.com/
公司代碼SOPH
上市日期Jul 23, 2021
CEOCamblong (Jurgi)
Sophia Genetics SA公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Jurgi Camblong, Ph.D.
Dr. Jurgi Camblong, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
2.65M
+7.89%
Dr. Vincent Ossipow, Ph.D.
Dr. Vincent Ossipow, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
443.81K
+12.21%
Dr. Zhenyu Xu, Ph.D.
Dr. Zhenyu Xu, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
396.61K
-4.26%
Mr. Troy M. Cox
Mr. Troy M. Cox
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
234.25K
+25.98%
Mr. Didier Hirsch
Mr. Didier Hirsch
Non-Executive Independent Director
Non-Executive Independent Director
133.93K
+79.72%
Mr. Ross J Muken
Mr. Ross J Muken
President
President
128.13K
+108.22%
Ms. Manuela Da Silva Valente
Ms. Manuela Da Silva Valente
Chief People Officer
Chief People Officer
60.38K
+51.32%
Dr. Philippe Menu, M.D., Ph.D.
Dr. Philippe Menu, M.D., Ph.D.
Chief Medical Officer and Chief Product Officer
Chief Medical Officer and Chief Product Officer
39.60K
-5.14%
Mr. George A. Cardoza
Mr. George A. Cardoza
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Jean-Michel Cossiery, Ph.D.
Mr. Jean-Michel Cossiery, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Jurgi Camblong, Ph.D.
Dr. Jurgi Camblong, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
2.65M
+7.89%
Dr. Vincent Ossipow, Ph.D.
Dr. Vincent Ossipow, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
443.81K
+12.21%
Dr. Zhenyu Xu, Ph.D.
Dr. Zhenyu Xu, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
396.61K
-4.26%
Mr. Troy M. Cox
Mr. Troy M. Cox
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
234.25K
+25.98%
Mr. Didier Hirsch
Mr. Didier Hirsch
Non-Executive Independent Director
Non-Executive Independent Director
133.93K
+79.72%
Mr. Ross J Muken
Mr. Ross J Muken
President
President
128.13K
+108.22%
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
由於公司未披露，未能獲取相關數據
地區USD
名稱
營收
佔比
Rest of EMEA
5.78M
31.53%
Italy
2.78M
15.19%
France
2.72M
14.82%
United States
2.66M
14.52%
Spain
1.63M
8.90%
其他
2.75M
15.04%
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月4日 週二
更新時間: 11月4日 週二
持股股東
股東類型
持股股東
持股股東
佔比
Alychlo NV
10.31%
Generation Investment Management LLP
10.01%
aMoon Fund
8.12%
Akre Capital Management, LLC
5.48%
Balderton Capital (UK) LLP
4.96%
其他
61.13%
持股股東
持股股東
佔比
Alychlo NV
10.31%
Generation Investment Management LLP
10.01%
aMoon Fund
8.12%
Akre Capital Management, LLC
5.48%
Balderton Capital (UK) LLP
4.96%
其他
61.13%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
16.17%
Venture Capital
13.08%
Family Office
10.36%
Investment Advisor
8.43%
Individual Investor
6.43%
Hedge Fund
1.05%
Bank and Trust
0.46%
Research Firm
0.06%
Pension Fund
0.03%
其他
43.93%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
76
26.89M
39.64%
-8.96M
2025Q2
89
36.69M
54.29%
-200.15K
2025Q1
93
36.63M
54.82%
-389.48K
2024Q4
93
32.50M
49.36%
-965.83K
2024Q3
91
34.60M
52.08%
+657.87K
2024Q2
92
32.44M
48.93%
+1.33M
2024Q1
93
31.91M
48.51%
+375.11K
2023Q4
91
30.61M
46.76%
-676.23K
2023Q3
91
30.34M
46.61%
-4.34M
2023Q2
90
31.34M
48.19%
-3.70M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Alychlo NV
6.99M
10.35%
--
--
Feb 15, 2025
Generation Investment Management LLP
6.79M
10.05%
--
--
Jun 30, 2025
aMoon Fund
5.51M
8.15%
+577.36K
+11.70%
Feb 15, 2025
Akre Capital Management, LLC
3.72M
5.5%
+1.48M
+66.22%
Jun 30, 2025
Balderton Capital (UK) LLP
3.36M
4.97%
--
--
Feb 15, 2025
Camblong (Jurgi)
2.65M
3.93%
+194.16K
+7.89%
Feb 15, 2025
Banque Pictet & Cie S.A.
2.21M
3.27%
-2.76K
-0.12%
Jun 30, 2025
Principal Global Investors (Equity)
1.40M
2.07%
+15.15K
+1.09%
Jun 30, 2025
Ossipow (Vincent)
443.81K
0.66%
+48.31K
+12.21%
Feb 15, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
iShares Health Innovation Active ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
iShares Health Innovation Active ETF
佔比0%
Fidelity Nasdaq Composite Index ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Sophia Genetics SA的前五大股東是誰？
Sophia Genetics SA的前五大股東如下：
Alychlo NV持有股份：6.99M佔總股份比例：10.35%。
Generation Investment Management LLP持有股份：6.79M佔總股份比例：10.05%。
aMoon Fund持有股份：5.51M佔總股份比例：8.15%。
Akre Capital Management, LLC持有股份：3.72M佔總股份比例：5.50%。
Balderton Capital (UK) LLP持有股份：3.36M佔總股份比例：4.97%。
Alychlo NV持有股份：6.99M佔總股份比例：10.35%。
Generation Investment Management LLP持有股份：6.79M佔總股份比例：10.05%。
aMoon Fund持有股份：5.51M佔總股份比例：8.15%。
Akre Capital Management, LLC持有股份：3.72M佔總股份比例：5.50%。
Balderton Capital (UK) LLP持有股份：3.36M佔總股份比例：4.97%。
Sophia Genetics SA的前三大股東類型是什麼？
Sophia Genetics SA 的前三大股東類型分別是：
Alychlo NV
Generation Investment Management LLP
aMoon Fund
Alychlo NV
Generation Investment Management LLP
aMoon Fund
有多少機構持有Sophia Genetics SA(SOPH)的股份？
截至2025Q3，共有76家機構持有Sophia Genetics SA的股份，合計持有的股份價值約為26.89M，占公司總股份的39.64% 。與2025Q2相比，機構持股有所增加，增幅為-14.66%。
哪個業務部門對Sophia Genetics SA的收入貢獻最大？
在FY2025Q2，--業務部門對Sophia Genetics SA的收入貢獻最大，創收--，占總收入的--% 。
